Japanese authorities have authorized stem cell-based therapies for Parkinson's disease and heart failure, marking a breakthrough in regenerative medicine.

Japan has authorized the use of two innovative therapies based on stem cells, representing a major step in regenerative medicine.

These treatments, which target Parkinson's disease and severe heart failure, could become available to patients in a few months. Sumitomo Pharma has obtained conditional approval for the Amchepry therapy, which involves transplanting stem cells into the brains of patients with Parkinson's. A study conducted by Kyoto University demonstrated the safety and efficacy of the treatment, with improvements observed in four out of seven patients monitored for two years.

Additionally, the ReHeart therapy, developed by the startup Cuorips, uses cardiac tissue grafts to improve heart function. These therapies are the first commercial medical products in the world based on iPS cells, developed by Nobel Prize laureate Shinya Yamanaka. The Japanese Minister of Health emphasized the importance of these innovations for patients, not only in Japan but also globally.